Ameer Hamza1, Dianna Roberts2, Shirley Su2, Randal S Weber2, Diana Bell3, Renata Ferrarotto2. 1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ahamza@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: diana.bell@mdanderson.org.
Abstract
BACKGROUND: Immune checkpoint inhibitors play an increasing role in oncologic care. PD-L1 expression is associated with survival and predicts response to PD-1 or PD-L1 inhibitors in a variety of tumors. Our aim is to evaluate the frequency and prognostic significance of PD-L1 expression in salivary duct carcinoma. DESIGN: We retrospectively evaluated the expression of PD-L1 by two different antibodies (PD-L1 28-8 and PD-L1 22C3) in salivary duct carcinomas. PD-L1 expression in at least 1% of tumor cells was considered immunoreactive. Kaplan-Meier analysis was performed to determine the impact of PD-L1 expression on survival; differences between survival curves were assessed by the chi-square test, and pairwise comparisons of factors were assessed with the log-rank test. RESULTS: A total of 113 patients' specimens were evaluated. Seventy-six (76%) of the patients were male. Mean age at time of presentation was 61.2 (SD = 12.4) years. PD-L1 expression was found in 26% of the samples. Median follow-up time was 36.6 months (range = 1.4-249 months). Overall survival at 3, 5 and 10 years were 52.6%, 37.9% and 25.6%, respectively. There was no statistical difference in survival between patients with PD-L1-immunoreactive tumors and those without, regardless of which antibody was used (chi2 result for all plots: p = 0.53; log rank test for pairwise comparison: p > 0.256). CONCLUSION: In our analysis, PD-L1 expression occurred in a small proportion of salivary duct carcinomas, usually at low levels, and did not correlate with survival. Its predictive value and utility in selecting patients with salivary duct carcinoma who might benefit from PD-1/PD-L1 inhibitors warrants further investigation.
BACKGROUND: Immune checkpoint inhibitors play an increasing role in oncologic care. PD-L1 expression is associated with survival and predicts response to PD-1 or PD-L1 inhibitors in a variety of tumors. Our aim is to evaluate the frequency and prognostic significance of PD-L1 expression in salivary duct carcinoma. DESIGN: We retrospectively evaluated the expression of PD-L1 by two different antibodies (PD-L1 28-8 and PD-L1 22C3) in salivary duct carcinomas. PD-L1 expression in at least 1% of tumor cells was considered immunoreactive. Kaplan-Meier analysis was performed to determine the impact of PD-L1 expression on survival; differences between survival curves were assessed by the chi-square test, and pairwise comparisons of factors were assessed with the log-rank test. RESULTS: A total of 113 patients' specimens were evaluated. Seventy-six (76%) of the patients were male. Mean age at time of presentation was 61.2 (SD = 12.4) years. PD-L1 expression was found in 26% of the samples. Median follow-up time was 36.6 months (range = 1.4-249 months). Overall survival at 3, 5 and 10 years were 52.6%, 37.9% and 25.6%, respectively. There was no statistical difference in survival between patients with PD-L1-immunoreactive tumors and those without, regardless of which antibody was used (chi2 result for all plots: p = 0.53; log rank test for pairwise comparison: p > 0.256). CONCLUSION: In our analysis, PD-L1 expression occurred in a small proportion of salivary duct carcinomas, usually at low levels, and did not correlate with survival. Its predictive value and utility in selecting patients with salivary duct carcinoma who might benefit from PD-1/PD-L1 inhibitors warrants further investigation.
Authors: Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow Journal: Lancet Oncol Date: 2016-05-27 Impact factor: 41.316
Authors: W van Boxtel; L D Locati; A C H van Engen-van Grunsven; C Bergamini; M A Jonker; E Fiets; S Cavalieri; S Tooten; E Bos; P Quattrone; G W Verhaegh; J A Schalken; L Licitra; C M L van Herpen Journal: Eur J Cancer Date: 2019-02-13 Impact factor: 9.162
Authors: Chiyun Wang; Elan Hahn; Elzbieta Slodkowska; Antoine Eskander; Danny Enepekides; Kevin Higgins; Danny Vesprini; Stanley K Liu; Michelle R Downes; Bin Xu Journal: Hum Pathol Date: 2018-08-01 Impact factor: 3.466
Authors: Meredith L Johnston; Shao Hui Huang; John N Waldron; Eshetu G Atenafu; Kelvin Chan; Bernard J Cummings; Ralph W Gilbert; David Goldstein; Patrick J Gullane; Jonathan C Irish; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Bayley; John Cho; Laura A Dawson; Andrew Hope; Jolie Ringash; Ian J Witterick; Brian O'Sullivan; John Kim Journal: Head Neck Date: 2015-07-15 Impact factor: 3.147
Authors: Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao Journal: Cancer Cytopathol Date: 2020-05-18 Impact factor: 5.284
Authors: Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia Journal: Head Neck Pathol Date: 2020-04-29